Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $113 | In Stock | |
5 mg | $278 | In Stock | |
10 mg | $447 | In Stock | |
25 mg | $847 | In Stock | |
50 mg | $1,130 | In Stock | |
100 mg | $1,530 | In Stock | |
1 mL x 10 mM (in DMSO) | $428 | In Stock |
Description | Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. |
In vitro | Evixapodlin exhibits an ability to increase the production of IFN-γ and Granzyme B in both CD8+ and CD4+ T cells in individuals with chronic hepatitis B (CHB). Additionally, Evixapodlin enhances the frequency of Granzyme B-positive cells among HBV-specific CD8+ and CD4+ T cells.[1] |
In vivo | Evixapodlin (10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment results in over 90% occupancy of the PD-L1 target on tumor cells. Evixapodlin effectively suppresses tumor growth in a mouse colorectal tumor model (MC38) that expresses human PD-L1.[1] |
Alias | PD-1/PD-L1-IN 7, GS-4224 |
Molecular Weight | 691.61 |
Formula | C34H36Cl2N8O4 |
Cas No. | 2374856-75-2 |
Storage | store at low temperature,keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45.0 mg/mL (65.1 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.